Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Nonausea and mild vomiting during the first 4-8 weeks are expected physiological responses to GLP-1 activation and do not indicate intolerance
Nausea: the most common side effect Nausea affected approximately 27% of retatrutide users in clinical trials across all doses
This common concern affects many patients considering or currently using GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound)
In clinical trials, Wegovy helped participants lose an average of 15% of their body weight over 68 weeks, and it's ideal for individuals with a BMI of 30 or higher, or 27 with related health conditions
Solutions like MeAgain centralize medication timing, meal logs, hydration, and side-effect visualization, letting users spot whether reflux clusters around doses, certain meals, or dehydration, and then act on that insight with their provider
